ARTICLE AUTHORS
ARTICLE INFO

Optional Modalities for Treatment of Patients with Severe Crimean-Congo Hemorrhagic Fever

AUTHORS

Batool Sharifi Mood 1 , Maliheh Metanat 1 , * , Roya Alavi Naini 1 , Masoud Mardani 2 , Ali Amjadi 1

1 Infectious Diseases and Tropical Medicine Research Center, Boo-Ali Hospital, Zahedan University of Medical Sciences, Zahedan, IR Iran

2 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

How to Cite: Sharifi Mood B, Metanat M, Alavi Naini R, Mardani M, Amjadi A. Optional Modalities for Treatment of Patients with Severe Crimean-Congo Hemorrhagic Fever, Arch Clin Infect Dis. Online ahead of Print ; 6(Suppl):27-9.

ARTICLE INFORMATION

Archives of Clinical Infectious Diseases: 6 (Suppl); 27-9
Article Type: Review Article

Crossmark

CHEKING

READ FULL TEXT
Abstract

Crimean-Congo hemorrhagic fever (CCHF) is an acute viral hemorrhagic fever caused by the Nairovirus in the family of Bunyaviridae, transmitted to humans by the bite of the Hyalomma tick or by direct contact with blood or tissue of an infected animal or human. CCHF is a severe disease with a high mortality rate ranging from 2% to 70%. Early diagnosis and treatment of CCHF infection is critical to rescue the patients and control the disease. The important approach to treatment of CCHF is based on general supportive measures, monitoring of the patients hematologic and coagulation status, with replacement of cells and other factors as needed, and the prompt use of ribavirin. In this article, we underline current therapeutic approaches to CCHF infection.

Keywords

© 0, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: